Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback